Senseonics (NYSE:SENS) Reaches New 52-Week High – Here’s What Happened

Senseonics Holdings, Inc. (NYSE:SENS)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $0.95 and last traded at $0.99, with a volume of 3044314 shares. The stock had previously closed at $0.91.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Senseonics in a research note on Friday, November 15th. StockNews.com started coverage on shares of Senseonics in a research note on Thursday, December 26th. They set a “sell” rating on the stock.

Senseonics Price Performance

The company’s 50-day moving average is $0.44 and its 200-day moving average is $0.40. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The firm has a market capitalization of $598.30 million, a price-to-earnings ratio of -7.73 and a beta of 0.64.

Senseonics (NYSE:SENS) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). The business had revenue of $4.26 million for the quarter, compared to analyst estimates of $4.02 million. Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. On average, research analysts expect that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current year.

Insider Buying and Selling at Senseonics

In other Senseonics news, CFO Frederick T. Sullivan purchased 124,933 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the purchase, the chief financial officer now owns 2,478,844 shares in the company, valued at $941,960.72. The trade was a 5.31 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Timothy T. Goodnow purchased 315,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was acquired at an average price of $0.31 per share, for a total transaction of $97,650.00. Following the purchase, the chief executive officer now owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SENS. FMR LLC raised its stake in Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after buying an additional 167,970 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Senseonics during the third quarter valued at approximately $117,000. Symmetry Partners LLC acquired a new stake in Senseonics during the third quarter valued at approximately $164,000. Cubist Systematic Strategies LLC raised its position in shares of Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after purchasing an additional 179,103 shares during the period. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.